KLDO — Kaleido Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$16.78m
- $1.10m
Brief: Kaleido Biosciences Reports Q2 Results
Brief: Kaleido Biosciences And The COPD Foundation Announce A Strategic Collaboration To Advance KB109 Into Phase 2 Clinical Trial
Kaleido Biosciences Inc expected to post a loss of 57 cents a share - Earnings Preview
Kaleido Biosciences Inc expected to post a loss of 57 cents a share - Earnings Preview
Kaleido Biosciences Inc expected to post a loss of 57 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-First Bancorp, Insight Enterprises, Lennar
Kaleido Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Kaleido Biosciences Says Entered Into Third Amendment To Loan And Security Agreement
Brief: Kaleido Biosciences Reports Q1 Loss Per Share Of $0.58
U.S. STOCKS ON THE MOVE-Applied Materials, Diamondback Energy, GameStop, NextDecade, Cinedigm
U.S. STOCKS ON THE MOVE-Applied Materials, GameStop, ViacomCBS, Cinedigm, Diamondback Energy
U.S. STOCKS ON THE MOVE-Brainstorm Cell Therapeutics, ASML, GameStop, PLBY Group
Kaleido rises on promising data from potential COVID-19 drug
Brief: Kaleido Biosciences Reports Positive Results From Non-IND Study Of KB109 In Patients With Mild-To-Moderate Covid-19
Brief: Kaleido Biosciences Reports Q4 loss Per Share $0.56
U.S. STOCKS ON THE MOVE-Peabody, Align, Cognizant, Qualcomm, Biogen, PayPal, Kaleido, HyreCar
Kaleido Biosciences down on $60 mln stock offering
Brief: Kaleido Biosciences Announces Pricing Of Public Offering Of Common Stock Of 5,250,000 Shares At $11.50 Per Share
Brief: Kaleido Biosciences Announces Proposed Public Offering Of Common Stock